>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

  • RMR +1%

M&A news:

  • TSRO +59.4% (to be acquired by GSK for $75/share in cash)
  • NBEV +15.8% (to merge with Morinda for total consideration of $85 mln in cash/stock)
  • TRCO +9.9% (to be acquired for $46.50/share in a cash transaction that is valued at $6.4 billion by Nexstar Media (NXST) )

Select FAANG related names showing strength:

  • STM +6%, AMD +5.2%, NVDA +5.1%, AMZN +4.7%, MU +4.2%, NFLX +3.6%, AAPL +3.3%, GOOG +2.9%, FB +2.1%

Select Macua gaming stocks trading higher:

  • LVS +6.3%, WYNN +6%, MLCO +5.4%, MGM +4%

Select oil/gas related names showing strength:

  • PBR +4.3%, DVN +4%, HAL +2.8%, RDS.A +2.5%, BP +2%, TOT +1.9%

Other news:

  • CLVS +30.7% (in sympathy with peer TSRO)
  • GBT +28.6% (plans to submit NDA after U.S. FDA agrees with proposal on an accelerated approval pathway for voxelotor for the treatment of sickle cell diseas)
  • VNDA +15.2% (announces 'positive' phase ii study results for tradipitant in patients with gastroparesis; Tradipitant met the primary endpoint)
  • ARGX +8.9% (announces exclusive, global collaboration and license agreement for cusatuzumab with J&J (JNJ) affiliate Cilag GmbH; also presents detailed data from its Phase 2 clinical trial of efgartigimod)
  • KPTI +7.7% (reports positive top-line Phase 2b SADAL data for Selinexor in patients with diffuse large B-cell lymphoma)
  • NIO +4.8% (November monthly delivery and production update)
  • BA +4.7% (positive Barrons article)
  • ARQL +4.6% (prelim results from its Phase 1 dose escalation study for ARQ 531)
  • GLYC +3.8% (presents new data on uproleselan-treated high risk patients with both relapsed/refractory and newly diagnosed AML) GM +3.5% (positive Barrons article)
  • IMGN +3.4% (reports initial data for CD123-Targeting IMGN632 demonstrating encouraging anti-leukemia activity and tolerable safety profile) . 

Analyst comments:

  • NDLS +7.5% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
  • ROKU +5.2% (upgraded to Buy from Neutral at DA Davidson)
  • CAT +4.9% (upgraded to Buy from Neutral at BofA/Merrill)
  • AVGO +3.3% (upgraded to Buy from Neutral at B. Riley FBR)
  • AGCO +2.6% (upgraded to Neutral from Underperform at BofA/Merrill)
  • FSLR +2.6% (upgraded to Neutral from Sell at Goldman)